Case report documenting allodynia and dysesthesia (painful abnormal skin sensations) in patients taking tirzepatide, adding to prior case reports of the same adverse effect with semaglutide, and establishing that this neurological adverse event occurs with both GLP-1-only and dual GLP-1/GIP agonist therapy across T2DM and obesity indications. Demonstrates this adverse effect is GLP-1R class-related rather than tirzepatide-specific. Provides pharmacovigilance evidence for incretin-class neurological adverse events—establishing allodynia and dysesthesia as under-recognized adverse drug reactions requiring prescriber awareness for patients presenting with new-onset cutaneous pain or abnormal sensations after GLP-1/GIP agonist initiation.
Ahern, Susan